---
title: "SPRY.US (SPRY.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SPRY.US/news.md"
symbol: "SPRY.US"
name: "SPRY.US"
parent: "https://longbridge.com/en/quote/SPRY.US.md"
datetime: "2026-03-14T14:48:09.495Z"
locales:
  - [en](https://longbridge.com/en/quote/SPRY.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SPRY.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SPRY.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/SPRY.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/SPRY.US/news.md)


# SPRY.US (SPRY.US) — Related News

### [Xspray Pharma Wins FDA Review Slot for Dasynoc Ahead of Planned 2026 Dual Launch](https://longbridge.com/en/news/278744994.md)
*2026-03-11T15:04:19.000Z*
> Xspray Pharma Wins FDA Review Slot for Dasynoc Ahead of Planned 2026 Dual Launch

### [ARS Pharmaceuticals: Q4 Earnings Insights](https://longbridge.com/en/news/278385309.md)
*2026-03-09T11:36:08.000Z*
> ARS Pharmaceuticals (NASDAQ:SPRY) reported Q4 earnings on March 9, 2026, beating estimates by 8.7% with an EPS of $-0.42

### [ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results](https://longbridge.com/en/news/278378740.md)
*2026-03-09T11:05:09.000Z*
### [ARS Pharmaceuticals 2025 10-K: $84.3M Revenue, $(1.74) EPS](https://longbridge.com/en/news/278371316.md)
*2026-03-09T10:15:01.000Z*
> ARS Pharmaceuticals reported fiscal 2025 revenue of $84.3 million, down 5% from 2024, with a net loss of $171.3 million,

### [ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales](https://longbridge.com/en/news/278370109.md)
*2026-03-09T10:10:02.000Z*
### [Pre-Market Earnings Report for March 9, 2026 :  ZIM, KFY, GBTG, NYAX, SPRY, HRTG, UMAC, FCEL, ACCO, DDD](https://longbridge.com/en/news/278166339.md)
*2026-03-07T05:10:17.000Z*
> On March 9, 2026, several companies are set to report earnings. ZIM expects a loss of $-1.01, a 121.67% decrease year-ov

### [Exploring ARS Pharmaceuticals's Earnings Expectations](https://longbridge.com/en/news/278117879.md)
*2026-03-06T14:02:12.000Z*
> ARS Pharmaceuticals (NASDAQ:SPRY) is set to announce its quarterly earnings on March 9, 2026, with analysts estimating a

### [](https://longbridge.com/en/news/277062671.md)
*2026-02-26T15:03:32.000Z*
> XSPRAY Pharmaceuticals: Resubmitting the FDA application for Dacisnock

### [Can Growing Patient And Provider Adoption Of Neffy Propel ARS Pharma's Stock Upward?](https://longbridge.com/en/news/277053492.md)
*2026-02-26T13:54:02.000Z*
> ARS Pharmaceuticals Inc.'s flagship product, neffy, has seen strong commercial growth since its launch, driven by increa